INTRODUCING

Tirzepatide, also known as LY3298176, is a synthetic, dual-acting peptide-based drug developed by Eli Lilly and Company. It acts as an agonist for both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Tirzepatide has been studied primarily for its potential in the treatment of type 2 diabetes and obesity, as it can enhance insulin secretion, suppress glucagon release, and decrease food intake, leading to improved glycemic control and weight loss. 

• Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial 

Juan Pablo Frias 1, Michael A Nauck 2, Joanna Van 3, Mark E Kutner 4, Xuewei Cui 5, Charles Benson 5, Shweta Urva 5, Ruth E Gimeno 5, Zvonko Milicevic 6, Deborah Robins 5, Axel Haupt 7 

Affiliations expand 

• PMID: 30293770 
• DOI: 10.1016/S0140-6736(18)32260-8 

• LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept 

Tamer Coskun 1, Shweta Urva 2, William C Roell 2, Hongchang Qu 2, Corina Loghin 2, Julie S Moyers 2, Libbey S O’Farrell 2, Daniel A Briere 2, Kyle W Sloop 2, Melissa K Thomas 2, Valentina  Pirro 2, David B Wainscott 2, Francis S Willard 2, Matthew Abernathy 2, LaRonda Morford 2, Yu Du 2, Charles Benson 2, Ruth E Gimeno 2, Axel Haupt 2, Zvonko Milicevic 3 

Affiliations expand 

• PMID: 35985340 
• DOI: 10.1016/j.cmet.2022.07.013